{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:32:42Z","timestamp":1770496362250,"version":"3.49.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["grant no. 82373359"],"award-info":[{"award-number":["grant no. 82373359"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project of Shanghai Municipal Health Commission","award":["grant no. 202140397"],"award-info":[{"award-number":["grant no. 202140397"]}]},{"name":"CSCO Cancer Research Fund","award":["grant no. Y-HR2020MS-0298, Y-pierrefabre202102-0066"],"award-info":[{"award-number":["grant no. Y-HR2020MS-0298, Y-pierrefabre202102-0066"]}]},{"name":"Chinese Young Breast Experts Research project","award":["grant no. CYBER-2021-001"],"award-info":[{"award-number":["grant no. CYBER-2021-001"]}]},{"name":"Beijing Science and Technology Innovation Medical Development Foundation Key Project","award":["grant no. KC2022-ZZ-0091-6"],"award-info":[{"award-number":["grant no. KC2022-ZZ-0091-6"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Combination of HER2-targeted therapy and endocrine therapy offers a more tolerable alternative to HER2-targeted chemotherapy regimens for estrogen receptor (ER)-positive, HER2-positive advanced breast cancer (ABC), but with compromised efficacy. The addition of cyclin-dependent kinase 4\/6 (CDK4\/6) inhibition may enhance the durability of anti-tumor responses, offering a potential chemotherapy-sparing alternative, although its role in the frontline setting remains uncertain. We performed a multicenter, single-arm, phase 2 clinical trial (PLEASURABLE) to assess the activity and safety of combining dalpiciclib with pyrotinib and endocrine therapy in patients receiving first- or second-line treatment for ER-positive and HER2-positive ABC.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>We enrolled patients with ER-positive and HER2-positive ABC between August 1, 2019, and November 28, 2022 in this prospective, investigator-initiated trial conducted at six centers in China. Patients received dalpiciclib (125\u2009mg once daily, on days 1\u201321 of each 28-day cycle) and pyrotinib (320\u2009mg once daily) plus endocrine therapy determined by the physician\u2019s choice (letrozole or fulvestrant). The primary endpoint was the objective response rate (ORR), while secondary endpoints included progression-free survival (PFS), duration of response (DOR), disease control rate (DCR), clinical benefit rate (CBR), safety, plasma pharmacokinetics (PK), and biomarker analysis. Efficacy was analyzed in the modified intention-to-treat population, comprising patients with at least one post-baseline tumor assessment. Safety was assessed in all patients who received at least one dose. A total of 51 patients were screened, and 48 were evaluable (median age was 52.5 years [range, 29\u201374]); 31 (64.6%) had prior HER2-target therapy, and 37 (77.1%) had received prior endocrine therapy. Thirty (62.5%) and 18 (37.5%) patients received the study treatment as first- and second-line HER2-targeted treatment for ABC, respectively. As of the data cutoff on December 11, 2024, six patients were lost to follow-up, and the median follow-up was 27.3 months (interquartile range, 24.8\u201330.5). The investigator confirmed ORR was 70.2% (95% CI [55.1, 82.7]), with a DCR of 100% (95% CI [92.5, 100]) and a CBR of 87.2% (95% CI [74.3, 95.2]). The median PFS was 22.0 months (95% CI [16.6, 26.6]), and the median DOR was 22.3 months (95% CI [16.4, 26.9]). No new safety signals were observed, and no treatment-related deaths occurred with only one (2.1%) grade 1 alopecia and no interstitial lung disease. Grade 3 or 4 treatment-related adverse events occurred in 68.8% and 12.5% of patients, respectively, mostly myelosuppression. PK analysis showed no major drug accumulation for dalpiciclib or pyrotinib over the treatment period. Of interest, no objective response was observed in three patients with detected <jats:italic>BRCA<\/jats:italic> mutations (n\u2009=\u20092) or increased <jats:sup>68<\/jats:sup>Ga-HER2 affibody uptake over the initial two cycles (n\u2009=\u20092). The findings of this study should be interpreted with caution due to the limited patient cohort and sample size in exploratory analyses.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The non-intravenous, chemotherapy-sparing combination of dalpiciclib, pyrotinib, and endocrine therapy demonstrated anti-tumor activity with a manageable safety profile in the frontline treatment of ER-positive, HER2-positive ABC, supporting its further evaluation as a potential alternative.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03772353\" xlink:type=\"simple\">NCT03772353<\/jats:ext-link><\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004669","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T17:50:57Z","timestamp":1753984257000},"page":"e1004669","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3208-3106","authenticated-orcid":true,"given":"Jian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujie","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lichun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-8362","authenticated-orcid":true,"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-699X","authenticated-orcid":true,"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"11","key":"pmed.1004669.ref001","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"DJ Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"pmed.1004669.ref002","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"SM Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"pmed.1004669.ref003","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10549-020-05728-w","article-title":"Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study","volume":"182","author":"B Xu","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"pmed.1004669.ref004","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.35730","article-title":"Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer","volume":"9","author":"S Zhao","year":"2019","journal-title":"Theranostics"},{"issue":"9938","key":"pmed.1004669.ref005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"P Cortazar","year":"2014","journal-title":"Lancet"},{"key":"pmed.1004669.ref006","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2016.03.012","article-title":"Hormone receptor\/human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going","volume":"46","author":"F Schettini","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"pmed.1004669.ref007","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1634\/theoncologist.2012-0414","article-title":"First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER","volume":"18","author":"D Tripathy","year":"2013","journal-title":"Oncologist"},{"issue":"6","key":"pmed.1004669.ref008","article-title":"Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation","volume":"13","author":"Y-C Wang","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"4","key":"pmed.1004669.ref009","doi-asserted-by":"crossref","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"WJ Gradishar","year":"2020","journal-title":"J Natl Compreh Cancer Netw"},{"issue":"12","key":"pmed.1004669.ref010","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"A Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"pmed.1004669.ref011","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/JCO.20.01894","article-title":"Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE","volume":"39","author":"SRD Johnston","year":"2021","journal-title":"J Clin Oncol"},{"issue":"33","key":"pmed.1004669.ref012","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"S Johnston","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"pmed.1004669.ref013","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","article-title":"Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis","volume":"20","author":"M Giuliano","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10226","key":"pmed.1004669.ref014","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"LM Spring","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"pmed.1004669.ref015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","article-title":"Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors","volume":"29","author":"S Goel","year":"2016","journal-title":"Cancer Cell"},{"issue":"6","key":"pmed.1004669.ref016","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","article-title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","volume":"21","author":"SM Tolaney","year":"2020","journal-title":"Lancet Oncol"},{"issue":"22","key":"pmed.1004669.ref017","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-20-0844","article-title":"Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial","volume":"26","author":"E Ciruelos","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pmed.1004669.ref018","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1158\/1078-0432.CCR-23-1209","article-title":"Overall survival and exploratory biomarker analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients","volume":"30","author":"SM Tolaney","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"11","key":"pmed.1004669.ref019","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"B Xu","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"pmed.1004669.ref020","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","article-title":"Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"24","author":"P Zhang","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"pmed.1004669.ref021","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"B Xu","year":"2021","journal-title":"Lancet Oncol"},{"key":"pmed.1004669.ref022","article-title":"Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study","volume":"1","author":"M Yan","year":"2020","journal-title":"Transl Breast Cancer Res"},{"key":"pmed.1004669.ref023","article-title":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial","volume":"383","author":"F Ma","year":"2023","journal-title":"BMJ"},{"key":"pmed.1004669.ref024","article-title":"Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer","volume":"12","author":"J Bu","year":"2023","journal-title":"Elife"},{"issue":"4","key":"pmed.1004669.ref025","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/cas.13957","article-title":"Preclinical characterization of SHR6390, a novel CDK 4\/6 inhibitor, in vitro and in human tumor xenograft models","volume":"110","author":"F Long","year":"2019","journal-title":"Cancer Sci"},{"key":"pmed.1004669.ref026","doi-asserted-by":"crossref","first-page":"775081","DOI":"10.3389\/fonc.2022.775081","article-title":"Dalpiciclib combined With pyrotinib and letrozole in women With HER2-positive, hormone receptor-positive metastatic breast cancer (LORDSHIPS): a phase Ib study","volume":"12","author":"J Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"pmed.1004669.ref027","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"J Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"pmed.1004669.ref028","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"SM Swain","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"pmed.1004669.ref029","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-022-06775-1","article-title":"Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study","volume":"197","author":"B Xu","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"10371","key":"pmed.1004669.ref030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"SA Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"19","key":"pmed.1004669.ref031","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"S Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"33","key":"pmed.1004669.ref032","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study","volume":"27","author":"B Kaufman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"pmed.1004669.ref033","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-21-3435","article-title":"Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for patients with hormone receptor-positive and HER2-positive metastatic breast cancer (SYSUCC-002)","volume":"28","author":"X Hua","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pmed.1004669.ref034","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1038\/s41467-023-41955-7","article-title":"Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial","volume":"14","author":"M Yan","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"pmed.1004669.ref035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12916-023-02943-2","article-title":"Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial","volume":"21","author":"Z-Y Hu","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"pmed.1004669.ref036","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41523-024-00646-2","article-title":"Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+\/HER2+ breast cancer patients with brain metastasis","volume":"10","author":"D Chen","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"pmed.1004669.ref037","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-021-00271-2","article-title":"A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor in Chinese patients with advanced breast cancer","volume":"9","author":"P Zhang","year":"2021","journal-title":"Biomark Res"},{"issue":"27","key":"pmed.1004669.ref038","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.2016.69.6179","article-title":"Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"35","author":"F Ma","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"pmed.1004669.ref039","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/annonc\/mdv577","article-title":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial","volume":"27","author":"G Gebhart","year":"2016","journal-title":"Ann Oncol"},{"key":"pmed.1004669.ref040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.breast.2022.07.012","article-title":"Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer","volume":"65","author":"A Viansone","year":"2022","journal-title":"Breast"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T17:51:07Z","timestamp":1753984267000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004669"}},"subtitle":[],"editor":[{"given":"Ricky W","family":"Johnstone,","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004669","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]}}}